Xponance Inc. Acquires 5,758 Shares of Cencora, Inc. (NYSE:COR)

Xponance Inc. grew its holdings in shares of Cencora, Inc. (NYSE:COR) by 9.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 68,295 shares of the company’s stock after buying an additional 5,758 shares during the period. Xponance Inc.’s holdings in Cencora were worth $15,345,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Swedbank AB lifted its holdings in shares of Cencora by 2.3% in the 3rd quarter. Swedbank AB now owns 1,394,449 shares of the company’s stock worth $313,863,000 after purchasing an additional 31,104 shares in the last quarter. United Bank lifted its holdings in shares of Cencora by 4.2% in the 3rd quarter. United Bank now owns 5,601 shares of the company’s stock worth $1,261,000 after purchasing an additional 225 shares in the last quarter. Oppenheimer & Co. Inc. lifted its holdings in shares of Cencora by 2.0% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 5,850 shares of the company’s stock worth $1,317,000 after purchasing an additional 115 shares in the last quarter. Mutual of America Capital Management LLC lifted its holdings in shares of Cencora by 2.9% in the 3rd quarter. Mutual of America Capital Management LLC now owns 21,528 shares of the company’s stock worth $4,846,000 after purchasing an additional 605 shares in the last quarter. Finally, Thrivent Financial for Lutherans lifted its holdings in shares of Cencora by 28.5% in the 3rd quarter. Thrivent Financial for Lutherans now owns 110,499 shares of the company’s stock worth $24,871,000 after purchasing an additional 24,492 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the sale, the executive vice president now owns 20,329 shares of the company’s stock, valued at approximately $4,649,648.88. This trade represents a 7.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Lazarus Krikorian sold 2,000 shares of Cencora stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $260.06, for a total value of $520,120.00. Following the completion of the sale, the chief accounting officer now directly owns 20,154 shares of the company’s stock, valued at approximately $5,241,249.24. This trade represents a 9.03 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 13,648 shares of company stock valued at $3,382,462. 10.80% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on COR. Evercore ISI increased their target price on Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a report on Thursday, February 6th. StockNews.com upgraded Cencora from a “hold” rating to a “buy” rating in a report on Wednesday, March 12th. Mizuho initiated coverage on Cencora in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price target for the company. JPMorgan Chase & Co. increased their price target on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Finally, Wells Fargo & Company increased their price target on Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a research report on Friday, March 14th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $280.20.

Cencora Trading Up 1.2 %

Shares of Cencora stock opened at $264.02 on Wednesday. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $281.45. The firm has a market cap of $51.20 billion, a PE ratio of 37.56, a P/E/G ratio of 1.31 and a beta of 0.51. The stock has a fifty day moving average price of $248.84 and a 200-day moving average price of $239.49. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Equities research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were issued a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.83%. The ex-dividend date was Friday, February 14th. Cencora’s dividend payout ratio (DPR) is currently 31.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.